Skip to main content

Pegvisomant Dosage

Medically reviewed by Last updated on Jan 24, 2024.

Applies to the following strengths: 10 mg; 15 mg; 20 mg; 25 mg; 30 mg

Usual Adult Dose for Acromegaly

Loading dose: 40 mg subcutaneously once under medical supervision
Initial dose: 10 mg subcutaneously once a day
Maintenance dose: 10 to 30 mg subcutaneously once a day
Maximum dose: 30 mg per day


Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Dosing based on baseline liver tests (LTs) of alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP).

Normal LT:

Elevated LT, but under 3 times (X) the upper limit of normal (ULN):

LT over 3 X ULN:

Patients who develop LT elevations or other signs of liver dysfunction on treatment:

LT over 3 but less than 5 X ULN (no hepatitis/liver injury symptoms, no increase in TBIL):

LT at least 5 X ULN, or transaminase elevations at least 3 X ULN with any TBIL increase (with/without hepatitis/liver injury symptoms):

Signs or symptoms suggesting hepatitis or other liver injury (e.g. jaundice, bilirubinemia, fatigue, nausea, vomiting, right upper quadrant pain, ascites, unexplained edema, easy bruising):

Dose Adjustments

Titrate dose to normalize serum IGF-I.



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Storage requirements:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.